Studying extracellular vesicles in immune thrombocytopenia

Studying extracellular vesicles in immune thrombocytopenia - Extracellulair vesicles in ITP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57039

Enrollment

Registered

2024-10-08

Start date

2024-10-15

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune thrombocytopenia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult patients with ITP Informed consent will be obtained

Exclusion criteria

Exclusion criteria: Patients with secondary ITP Patients with antiplatelet therapy

Design outcomes

Primary

Measure	Time frame
Concentration of EVs in ITP patients; Wilcoxon signed rank tests will be used to compare EV concentrations between groups. Of interest are EVs derived from platelets (CD61+), activated platelets (CD62p+) and erytrocytes (CD235a+).	—

Secondary

Measure	Time frame
Association of (platelet-derived) EVs with age, sex and current/past therapy.	—

Countries

Netherlands

Outcome results